Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030552 (
paresis
)
5,831
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activated protein C resistance in
factor V Leiden
mutation is currently the most frequent hereditary defect accompanied by high risk of thromboembolism. Thromboembolism often develops in the presence of additional risk factors such as pregnancy, birth, taking oral contraceptives, immobilization and surgical operations. A case of multiple phlebothrombosis following caesarean section in heterozygous
factor V Leiden
mutation evidenced post partum is reported. The patient developed extensive phlebothrombosis in both legs on postoperative day three despite preventive thrombosis treatment with low-molecular heparin. She also suffered from short-term incomplete
paresis
of her left arm and epileptic seizure with typical grand mal symptoms. MRI showed partial thrombosis of the superior sagittal sinus and the transverse sinus.
...
PMID:[Multiple phlebothrombosis following cesarean section due to heterozygous factor V Leiden mutation detected post partum]. 1061 20
From the information presented in this article, it can be concluded that clinical suspicion of VTE should be increased in patients with a history of VTE, recent surgery, spinal cord injury, trauma, or malignancy. A variety of medical illnesses also increase the risk of venous thrombosis, including congestive heart failure, myocardial infarction, stroke with
paresis
, nephrotic syndrome, cigarette smoking, and obesity. Hypercoagulable states, such as antithrombin III deficiency, protein C deficiency, protein S deficiency, or
factor V Leiden
mutation should be considered in those patients who develop VTE in the absence of known risk factors. Additionally, the presence of vena caval filters does not exclude the possibility of PE or recurrent DVT. With a careful assessment of risk, physicians can hope to increase the diagnostic yield of VTE and decrease the significant morbidity and mortality of caused by this disease.
...
PMID:Epidemiology of venous thromboembolic disease. 1176 74
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are distinct but related aspects of the same dynamic disease process known as venous thromboembolism (VTE). An estimated 200,000 new cases occur in the United States every year, including 94,000 with PE, resulting in an incidence of 23 per 100,000 patients per year-cases. Without treatment, pulmonary embolism is associated with a mortality rate of approximately 30%, causing nearly 50,000 deaths per year. Moreover, based on post-mortem studies, two-thirds of the patients with pulmonary emboli remain undiagnosed. Clinically, PE may present as (1) isolated dyspnea, (2) pleuritic pain and/or hemoptysis, and (3) circulatory collapse. However, clinical history and examination can be notoriously misleading in reaching a diagnosis. A number of acquired etiologic risk factors (predispositions) are associated with a tendency to develop VTE. These include increasing age, immobilization, surgery, trauma, hospital or nursing home confinement, malignancy, neurologic disease with extremity
paresis
, as well as certain types of oral contraception and hormone replacement therapy. In addition, a variety of genetic risk factors, such as
factor V Leiden
, protein S or C deficiency have also been identified. However, in at least half of the instances, no predisposing factors can be identified (idiopathic PE). In the majority of cases thromboemboli originate in the deep veins of the calf or pelvis. The pathogenic conditions for VTE comprise a triad of factors and include (1) venous stasis, (2) hypercoagulable states, and (3) vascular endothelium injury. Occlusion of pulmonary arteries has variable and transient clinical and pathophysiologic consequences, involving both mechanical and reflex effects of vascular occlusion with a consecutive perfusion defect as well as the release of vasoactive and other inflammatory mediators. The objectives of this article are to present an overview of the etiologic and pathogenic factors promoting VTE as well as the pathophysiologic and inflammatory processes following PE.
...
PMID:Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. 1258 87
We report clinical findings, risk factors and neurological and cognitive long-term outcome in three Italian children aged 7, 8 and 5, respectively, who experienced cerebral venous sinus thrombosis (CVST). All children presented with headache, associated to nausea, vomiting and papilloedema. None suffered from epileptic seizures. In two of them a
paresis
of the sixth cranial nerve with diplopia was found. Diagnosis was confirmed by magnetic resonance imaging angiography (angio MRI) in all cases. In all patients plasma levels of protein C, protein S, antithrombin III (AT III), antiphospholipid antibodies (ApA) and homocysteine were detected. Furthermore,
factor V Leiden
mutation, prothrombin mutation G20210A and MTHFR mutation were searched for. A Protein C reduction was detected in all patients at onset; this finding, however, was not confirmed at follow-up in all of them. At one-year follow-up, neurological examination was normal in all children and neuropsychological assessment, aimed at excluding linguistic and non-linguistic cognitive deficits, revealed normal performances in two of them. In the third child, cognitive assessment confirmed a previously diagnosed developmental dyslexia.
...
PMID:Cerebral venous sinus thrombosis in childhood: clinical aspects and neurological and cognitive long-term outcome in three cases. 1562 88
Venous thromboembolism is predominantly a disease of older age. The average annual incidence rate of venous thromboembolism among Caucasians is 1 per 1,000 person-years. Common independent VTE risk factors include hospitalization, active cancer, neurological disease with extremity
paresis
and, among women, oral contraceptives, pregnancy and the puerperium, and hormone therapy. Inherited reductions in plasma natural anticoagulants (antithrombin, protein C, or protein S) have long been recognized as uncommon but potent risk factors for venous thromboembolism. Activated protein C resistance (
factor V Leiden
), G20210 variant in the prothrombin gene have been recently added to the list of inherited disorders predisposing to thrombosis. Those latter frequent inherited factors interact with environmental risk factors such as oral contraceptives, pregnancy, hormone therapy.
...
PMID:[Incidence and risk factors for venous thromboembolism]. 1762 16